# Ruboxistaurin in New York Heart Failure Classification III-IV Patients

> **NCT02769611** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of Tennessee**

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Ruboxistaurin

## Key facts

- **NCT ID:** NCT02769611
- **Lead sponsor:** University of Tennessee
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06-28
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding
- **Last updated:** 2022-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02769611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02769611, "Ruboxistaurin in New York Heart Failure Classification III-IV Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02769611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*